•
Mar 31, 2024

IDEXX Q1 2024 Earnings Report

IDEXX's Q1 2024 results were announced, demonstrating revenue growth driven by the Companion Animal Group and Water segments.

Key Takeaways

IDEXX Laboratories reported a 7% increase in revenue for Q1 2024, reaching $964 million. EPS increased by 10% to $2.81. The company is updating its full year revenue growth outlook range to 6.5% - 8.5% as reported and 7% - 9% organic.

Revenues reached $964 million, a 7% increase as reported and organic.

Companion Animal Group (CAG) grew by 7% as reported and organic.

Water revenue increased by 11% as reported and organic.

Earnings per diluted share (EPS) were $2.81, a 10% increase as reported.

Total Revenue
$964M
Previous year: $900M
+7.1%
EPS
$2.81
Previous year: $2.55
+10.2%
Gross Profit
$593M
Previous year: $543M
+9.2%
Cash and Equivalents
$397M
Previous year: $111M
+256.9%
Free Cash Flow
$168M
Previous year: $144M
+16.6%
Total Assets
$3.35B
Previous year: $2.81B
+19.4%

IDEXX

IDEXX

IDEXX Revenue by Segment

IDEXX Revenue by Geographic Location

Forward Guidance

IDEXX is updating its full year revenue growth outlook range to 6.5% - 8.5% as reported and 7% - 9% organic. The Company maintained its full year reported operating margin outlook of 30.2% - 30.7%. The Company updated its EPS outlook range to $10.82 - $11.20.

Positive Outlook

  • Updated revenue growth outlook range to 6.5% - 8.5% as reported and 7% - 9% organic.
  • CAG Diagnostics recurring revenue growth outlook range of 6.5% - 8.5% as reported and 7.5% - 9.5% organic.
  • Maintained full year reported operating margin outlook of 30.2% - 30.7%.
  • Projected full year operating margin profit expansion of 20 - 70 basis points.
  • Updated EPS outlook range to $10.82 - $11.20.

Challenges Ahead

  • Includes a $35 million negative impact from the recent strengthening of the U.S. dollar.
  • Reduction of 1% to the high end of the organic revenue growth range to reflect near-term moderation in U.S. clinical visit growth trends.
  • Reduction of $0.08 at midpoint in EPS outlook, reflecting ~$0.11 of negative foreign exchange rate impact compared to previous guidance.
  • Projected full year operating margin profit expansion of 20 - 70 basis points is net of a ~40 basis point negative growth impact from lapping a customer contract resolution payment in Q1 2023.
  • Updated EPS growth outlook is 8% - 11% as reported and 9% - 13% on comparable basis, net of a ~2% negative growth impact from lapping a customer contract resolution payment in Q1 2023.

Revenue & Expenses

Visualization of income flow from segment revenue to net income